Research
RIPK1 inhibition limits expansion of pathogenic double-negative T cells in preclinical autoimmune lymphoproliferative syndrome models
Science · By Jingjing Li, Yayun Du, Jiaying Qiu, Xiaoliang Yu, Zhanhui Li, Haikuo Ma, Wei Zhang, Xiangping Xu, Qiuye Li, Cong Zhao, Dongmei Cao, Rui Li, Zhizhuo Du, Hu Liu, Xiaohu Zhang, Junjie Fan, Shaoyan Hu & Sudan He ·
The Brief
- A preclinical study reports that RIPK1 inhibition limits the expansion of pathogenic double-negative T cells in autoimmune lymphoproliferative syndrome models.
- The work was published in Science Translational Medicine, Volume 18, Issue 876, in November 2026.
Why it matters
It identifies RIPK1 inhibition as a possible way to restrain disease-driving T cells in autoimmune lymphoproliferative syndrome, though the evidence is preclinical.
Who’s affected
- immunologists
- researchers studying autoimmune lymphoproliferative syndrome
- #ripk1
- #t cells
- #autoimmunity
- #lymphoproliferative syndrome
- #immunology
Science Translational Medicine, Volume 18, Issue 876 , November 2026.